Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2

Autor: Michael Wang, Preetesh Jain, T Linda Chi, Sheree E Chen, Amy Heimberger, Shiao-Pei Weathers, Lianqing Zheng, Arati V Rao, John M Rossi
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Druh dokumentu: article
ISSN: 2051-1426
DOI: 10.1136/jitc-2020-001114
Popis: Cerebral edema following chimeric antigen receptor (CAR) T-cell therapy can be fatal. ZUMA-2 is a pivotal phase 2, multicenter study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in relapsed/refractory mantle cell lymphoma. We describe a 65-year-old patient in ZUMA-2 who developed cerebral edema following CAR T-cell therapy and had complete recovery after multimodality clinical intervention including rabbit antithymocyte globulin (ATG). Biomarker results show early and robust CAR T-cell expansion and related induction of inflammatory cytokines, followed by rapid declines in CAR T-cell and proinflammatory cytokine levels after ATG administration. This clinical profile highlights a potential relevance of ATG in treating severe CAR T-cell-related neurotoxicity.
Databáze: Directory of Open Access Journals